Question
Oseltamivir
Q5 3 marks Short Notes ★ ✓
Answer
Oseltamivir is a neuraminidase inhibitor.
Mechanism of action
Blocks the viral enzyme neuraminidase, required for the release of newly formed influenza virus particles from infected host cells, thereby limiting the spread of infection to adjacent cells
Uses
Treatment of influenza A and B (most effective when started within 48 hours of symptom onset)
Prophylaxis in exposed high-risk individuals
Adverse effects
Nausea, vomiting
Headache
Neuropsychiatric effects (rare, more reported in paediatric patients)
1 Antiviral Drugs
Other Years Asked
1 A Resident surgeon consults a physician with the following problem: During a surgical
procedure he got exposed to a 26-year-old female patient’s blood and saliva through a
piercing injury on the finger. A needle had penetrated across his gloves and skin to a
depth of 2–3 mm, but was withdrawn immediately and the area washed under running
water. On enquiry, the patient revealed that one year back she had tested HIV (Human
Immunodeficiency Viru 2024 June (Supplementary) (2019 Scheme) Essay · 15 marks 2 ( 2022 July (Supplementary) (2019 Scheme) Essay · 8 marks 3 Pharmacological basis for the use of Zidovudine in HIV. 2023 July (Supplementary) (2019 Scheme) Short Answer · 4 marks 4 Write briefly on post-exposure prophylaxis of HIV infection after a needlestick injury. 2024 December (Supplementary) (2019 Scheme) Short Answer · 4 marks 5 Acyclovir 2023 January (Supplementary) (2019 Scheme) Short Answer · 4 marks 6 Protease inhibitors 2019 February (2010 Scheme) Short Note · 3 marks 7 Protease inhibitors in HIV infection. 2017 February (2010 Scheme) Short Note · 3 marks 8 Acyclovir 2024 March (Supplementary) (2010 Scheme) Short Note · 3 marks 9 For herpes virus infection 2018 July (Supplementary) (2010 Scheme) Short Answer · 1 mark 10 Antiretroviral drugs 2016 October (Supplementary) (2010 Scheme) Short Answer · 1 mark 11 Mechanism of action of oseltamivir. 2013 September (Supplementary) (2010 Scheme) Short Answer · 1 mark 12 Non nucleoside reverse transcriptase inhibitors 2016 February (2010 Scheme) Short Answer · 1 mark 13 H1N1 viral infection. 2015 September (Supplementary) (2010 Scheme) Short Answer · 1 mark 14 Mechanism of action of acyclovir 2013 April (2010 Scheme) Short Answer · 1 mark 15 Retro viral infections 2014 September (Supplementary) (2010 Scheme) Short Answer · 1 mark 16 Post exposure prophylaxis of HIV (acquired immunodeficiency syndrome) 2017 August (Supplementary) (2010 Scheme) Short Answer · 1 mark 17 Herpes zoster infection. 2017 February (2010 Scheme) Short Answer · 1 mark 18 Protease inhibitors 2018 February (2010 Scheme) Short Answer · 1 mark 19 HIV infection.. 2013 September (Supplementary) (2010 Scheme) Short Answer · 1 mark 20 Non-nucleoside Reverse Transcriptase Inhibitors (nNRTIs) 2020 February (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 21 Antiretroviral drugs 2023 July (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 22 Protease inhibitors 2025 March (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 23 Neuraminidase inhibitors 2022 May (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 24 Anti-herpes virus drugs 2021 December (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 25 Anti Hepatitis B viral drugs 2021 May (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 26 Post-exposure prophylaxis in HIV infection 2022 October (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 27 Anti-influenza virus drugs 2025 August (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 28 Antiretroviral drugs. 2023 January (Supplementary) (2019 Scheme) Short Answer · 0.2 marks 29 Drugs for herpes simplex 2022 February (2019 Scheme) Short Answer · 0.2 marks 30 Drugs to treat Influenza. 2023 July (Supplementary) (2019 Scheme) Short Answer · 0.2 marks 31 Neuraminidase inhibitors 2024 March (Supplementary) (2019 Scheme) Short Answer · 0.2 marks 
